Innovative Advancements in COVID Testing

Jon has over 17 years of experience in the clinical lab industry. Spearheading trends in the industry, he created one of the nation's first firms solely dedicated to recruiting for clinical laboratories as well as the first firm dedicated to buying and selling CLIA labs. Jon oversees all consulting, lab director services, and recruiting for Lighthouse Lab Services.

Joseph Sgherza has more than 30 years of clinical research experience across multiple therapeutic areas with pharmaceutical, government, academic, and clinical research organizations and is an operational Global Infectious Disease expert in Phase I-IV development and implementation. His vision for global health is built on three tenets: developing techniques and tools to increase awareness in countries predisposed to infectious disease; decreasing the delays in assessing needs during epidemic and pandemic outbreaks; and rapidly delivering on-the-ground aid and research to combat disease. Through the course of his career, Mr. Sgherza has overseen 175 database locks for landmark trials of pivotal drugs, devices, and vaccines. His global network results from living, training, and forming clinical research centers in such areas as India, Latin America, and Ukraine. Many of his former students are industry and academic leaders who continuing using and teaching others “best practices” in GCP/ICH. In addition to Integrum Scientific, he serves in an advisory capacity to numerous commercial international pharmaceutical companies, NGOs, and government agencies.

He is responsible for overseeing both companies’ administrative, R&D, sales, and operational activities. Leinco Technologies’ brand is well known in the industry and has become associated with developing, manufacturing, and supplying the highest quality, affordably priced In vivo functional grade recombinant proteins and monoclonal antibodies used in preclinical studies at both academic institutes and biopharmaceutical companies. The company has built the reputation of being the leading supplier of high purity bulk monoclonal antibodies at the gram to kilogram scale and has demonstrated sustained profitability with controlled annual revenue increases of 25%-30%.
Mr. Leinert has 35 years of experience in research, manufacturing, and marketing of early discovery medical research products and active components for medical and veterinary diagnostic tests. He worked as a biochemist in the immunochemical department of Sigma-Aldrich Chemical Company from 1983 - 1988 and was the key person responsible for the scale-up of immunochemical manufacturing. Mr. Leinert also worked as a protein biochemist for Coulter Corporation from 1988 - 1990 in the R&D department of the Immunology Division where he developed purification procedures for proteins used in FDA-approved diagnostic kits.